Pfizer (NYSE:PFE) Stock Rating Lowered by StockNews.com

Pfizer (NYSE:PFEGet Rating) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Monday.

Other equities analysts have also recently issued reports about the company. Mizuho dropped their price objective on Pfizer from $56.00 to $55.00 in a research note on Thursday, February 10th. Citigroup lifted their target price on Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 5th. Sanford C. Bernstein lifted their target price on Pfizer from $44.00 to $65.00 and gave the stock a “market perform” rating in a research note on Monday, January 3rd. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating and set a $52.00 target price on the stock. in a research note on Tuesday, February 15th. Finally, UBS Group upgraded Pfizer from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $52.00 to $60.00 in a research note on Monday, December 13th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $58.00.

Shares of PFE opened at $53.11 on Monday. Pfizer has a 12-month low of $36.89 and a 12-month high of $61.71. The business’s fifty day moving average is $50.95 and its 200 day moving average is $50.72. The company has a quick ratio of 1.19, a current ratio of 1.40 and a debt-to-equity ratio of 0.47. The stock has a market cap of $299.95 billion, a P/E ratio of 13.79, a P/E/G ratio of 0.80 and a beta of 0.77.

Pfizer (NYSE:PFEGet Rating) last issued its earnings results on Tuesday, February 8th. The biopharmaceutical company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.23. Pfizer had a return on equity of 34.53% and a net margin of 26.97%. The company had revenue of $23.84 billion for the quarter, compared to analysts’ expectations of $24.20 billion. During the same period last year, the business earned $0.42 EPS. Pfizer’s quarterly revenue was up 104.0% compared to the same quarter last year. On average, analysts expect that Pfizer will post 7.28 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of PFE. Wealthcare Capital Management LLC bought a new stake in Pfizer in the 1st quarter worth approximately $222,000. Blue Fin Capital Inc. lifted its position in Pfizer by 0.6% in the 1st quarter. Blue Fin Capital Inc. now owns 44,948 shares of the biopharmaceutical company’s stock worth $2,326,000 after buying an additional 270 shares during the last quarter. Griffin Asset Management Inc. lifted its position in Pfizer by 14.5% in the 1st quarter. Griffin Asset Management Inc. now owns 71,278 shares of the biopharmaceutical company’s stock worth $3,690,000 after buying an additional 9,041 shares during the last quarter. Wedge Capital Management L L P NC lifted its position in Pfizer by 12.2% in the 1st quarter. Wedge Capital Management L L P NC now owns 663,232 shares of the biopharmaceutical company’s stock worth $34,336,000 after buying an additional 72,041 shares during the last quarter. Finally, Sara Bay Financial lifted its position in Pfizer by 7.8% in the first quarter. Sara Bay Financial now owns 18,722 shares of the biopharmaceutical company’s stock valued at $969,000 after purchasing an additional 1,360 shares during the last quarter. Hedge funds and other institutional investors own 64.96% of the company’s stock.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.